SCHEMBL23213143

SCHEMBL23213143

Cc1c(Cl)cc(N)cc1CN1CCC(N(C)C)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 4/20 0.40
PARP2 Q9UGN5 1/20 0.40
RORC P51449 1/20 0.39
CXCR3 P49682 4/20 0.37
CXCR4 P61073 1/20 0.37
TNKS O95271 1/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
PTPN11 Q06124 1/20 0.34
NPY1R P25929 3/20 0.34
MAP4K4 O95819 1/20 0.34
TSHR P16473 1/20 0.34
ABL1 P00519 1/20 0.34
LCK P06239 1/20 0.34
FYN P06241 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29796167 1.00 PARP1 (0.40) PARP1PARP2RORCCXCR3CXCR4
SCHEMBL27290092 0.86 RORC (0.40) PARP1PARP2RORCCXCR3CXCR4
SCHEMBL29795985 0.79 LMNA (0.51) PARP1PARP2RORCALDH1A1SMN1; SMN2
SCHEMBL23213367 0.79 LMNA (0.51) PARP1PARP2RORCALDH1A1SMN1; SMN2
SCHEMBL29716296 0.79 LMNA (0.50) ALDH1A1MAPTSMN1; SMN2TDP1
SCHEMBL23213589 0.79 LMNA (0.50) ALDH1A1MAPTSMN1; SMN2TDP1
SCHEMBL23212903 0.78 PARP1 (0.43) PARP1PARP2RORCTNKSALDH1A1
SCHEMBL23213615 0.78 CNR1 (0.41) PARP1PARP2DDR1
SCHEMBL29739690 0.77 CYP2A13 (0.51) MAPTSMN1; SMN2TDP1
SCHEMBL23213276 0.77 CYP2A13 (0.51) MAPTSMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2024-07-04 US disclosed
EP-4313047-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS Monte Rosa Therapeutics, Inc. (US) 2024-02-07 EP disclosed
US-20220242846-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2022-08-04 US disclosed
WO-2021069705-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS (CH) 2021-04-15 WO disclosed
WO-2021069705-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS (CH) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS UPF1, NSUN2, RTF2 PARP1 4553/4885PARP2 3080/4885RORC 3504/4885
US-20220242846-A1 ISOINDOLINONE COMPOUNDS AOC2, AOC3, INF2 PARP1 4442/4885PARP2 2999/4885RORC 2409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.